EBE, European Biopharmaceutical Trade Association, Announces Its Leadership At BioVision, Lyon. (6 June – Lyon, FRANCE) - Today the European Biopharmaceutical Enterprises, EBE, is pleased to announce its newly elected Board of Directors for the term 2014-2016. The announcement is being made following the meeting of the EBE Board in the context of the EFPIA Annual Meetings (European Federation of Pharmaceutical Industries and Associations) and the BioVision International Conference in Lyon. EBE’s 15 C-level strong board continues to be headed by Roberto Gradnik, Strategic Board Advisor and former CEO of Stallergenes, who was re-elected for a second term. Mr Gradnik has brought a significant change in the trade association’s new strategic direction, enhancing its focus on emerging sciences and advanced technologies. To support the strategic direction towards advanced therapies and innovation ecosystem, EBE members elected Eduardo Bravo, CEO TiGenix, as Vice-President. Mr. Bravo brings invaluable experience from the field of advanced therapies, bridging the gap between the lab and personalised medicines supported by a thriving innovation ecosystem. Didier Malherbe, Managing Director, UCB Belgium and Vice-President of Public Affairs, was re-elected as Treasurer of EBE, thanks to his efforts towards a financially sustainable EBE. “I am delighted to continue working with such a dedicated group of senior leaders and experts in the biopharmaceutical field. Together, we steer EBE in its efforts to advance the innovation ecosystem, and translation of emerging sciences into concrete solutions that will help patients in Europe”, stated Titta Rosvall-Puplett, Executive Director EBE. “Excellent attendance at the BioVision Investor Conference held yesterday – an event to which EBE members received free registration thanks to partnership with BioVision and EFPIA – demonstrated the importance of collaborative networks and the need for a multidisciplinary approach when it comes to financing innovation in Europe. I invite everyone to explore more about the work of EBE via our new video” and meet our new board members (list below) stated Roberto Gradnik, President of EBE. EBE Board Composition 2014 – 2016 EBE#President:## Roberto#Gradnik,## Strategic)Board)Advisor,)Stallergenes) EBE#Vice#President:## Eduardo#Bravo,## Chief)Execu9ve)Officer,)) TiGenix) EBE#Treasurer:## Didier#Malherbe,# UCB)Vice)President)Public)) Affairs)&)Managing)Director,)) UCB)Belgium) Eugenio#Aringhieri# Chief)Execu9ve)Officer,)) Dompé)Group) Jack#Barbut,## Chief)Execu9ve)Officer,)) NovImmune) Liz#Barre@,## President,)Europe,)) Global)Innova9ve)Pharma,)) Pfizer) )) ) )) Ahmed#Bouzidi,)) Chief)Execu9ve)Officer,)) Vaxeal) Andrea#Chiesi,#CEO,# Holostem)Advanced)Therapies,)) Director)R&D)Project)PorSolio)) Management,)) Chiesi)Farmaceu9ci) ))Christophe#Jean# Carlo#Incer?,# Chief)Medical)Officer)Genzyme) Corpora9on## #Pascale#Riche@a,## )Vice)President)Western) )Europe)&)Canada)) )Opera9ons,)AbbVie) Jochen#Maas,# General)Manager)R&D)) Sanofi)Aven9s)Germany) Execu9ve)Vice)President,)) Corporate)Strategy,)) Business)Development,)) Alliances)and)M&A,)Ipsen) )) )) Eric#Halioua# Chief)Execu9ve)Officer,) Promethera)Biosciences) Carsten#Thiel) Head)of)Europe,)) Amgen) Ralf#Schumacher,## Head)of)Large)Molecule)) Research,) Roche) 1 / 2 About EBE The European Biopharmaceutical Enterprises (EBE), a specialised group of European Federation of Pharmaceutical Industries and Associations (EFPIA) is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. It has 50 member companies - majority of which are small and medium sized companies - engaged in the research, development, manufacturing and marketing of new medicinal products using biotechnology. For more information on EBE, see this new video on EBE (http://ebe-biopharma.eu/mediacentre/videos ), its work and its current goals Media Contact Titta Rosvall-Puplett Executive Director, European Biopharmaceutical Enterprises +32 2 626 25 64 [email protected] 2 / 2
© Copyright 2024 ExpyDoc
